União Europeia -
português -
EMA (European Medicines Agency)
sarclisa
sanofi winthrop industrie - isatuximab - mieloma múltiplo - agentes antineoplásicos - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.
Brasil -
português -
ANVISA (Agência Nacional de Vigilância Sanitária)
sarclisa
sanofi medley farmacÊutica ltda. - isatuximabe - antineoplasico
Brasil -
português -
ANVISA (Agência Nacional de Vigilância Sanitária)
sylvant
janssen-cilag farmacÊutica ltda - siltuximabe - imunosupressor